46 completed, 12 terminated, 9 recruiting, 8 active not recruiting. 46 Phase 2, 21 Phase 3, 16 Phase 1, 2 Early Phase 1, 1 Not applicable.
Follow Casodex: new trials by email Literature Review of Casodex trials Research Report on Casodex
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3 - Prostate Cancer, Recurrent Prostate Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 20 | 2026-10-31 | 2026-09-11 |
| Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT Leuprolide, Degarelix, Relugolix - Prostate Cancer, Localized Prostate Carcinoma | Phase 2 | Recruiting | Baptist Health South Florida | 50 | 2026-07-29 | 2026-08-06 |
| A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer Bicalutamide, Biopsy Procedure, Biospecimen Collection - Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 1 | Recruiting | University of Wisconsin, Madison | 80 | 2026-06-25 | 2026-09-30 |
| Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer Gonadotropin Releasing Hormone Agonists and Antagonists, Bicalutamide, Biopsy Procedure - High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2025-04-16 | 2025-09-23 | |
| A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma Bicalutamide, Intensity-modulated radiation therapy (IMRT) - Recurrent Glioblastoma, Recurrent High-grade Glioma | Phase 1 | Withdrawn | University of Nebraska | 2025-04-08 | 2025-07-22 | |
| REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial Abiraterone Acetate, Bicalutamide, Biospecimen Collection - Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8 | Phase 3 | Recruiting | Emory University | 72 | 2025-01-31 | 2026-02-24 |
| Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC Bicalutamide in combination with Sunitinib - Carcinoma, Renal Cell | Phase 1 / Phase 2 | Recruiting | State University of New York at Buffalo | 28 | 2024-10-01 | 2026-04-01 |
| Bicalutamide Therapy in Young Women With NAFLD and PCOS Bicalutamide 50 mg, Placebo - NAFLD, PCOS | Phase 1 | Recruiting | University of California, San Francisco | 50 | 2024-02-14 | 2026-05-29 |
| Phase II Dutasteride in Combination With CAB vs CAB in SDC Goserelin 10.8 mg, Bicalutamide 50 mg, Dutasteride 0.5 mg - Salivary Duct Carcinoma | Phase 2 | Recruiting | Radboud University Medical Center | 26 | 2022-09-27 | 2025-06-04 |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial Bicalutamide, Buserelin, Darolutamide - Prostate Adenocarcinoma | Phase 3 | Active not recruiting | NRG Oncology | 2050 | 2021-12-06 | 2026-08-17 |
| Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer Abiraterone Acetate, Bicalutamide, Degarelix - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 70 | 2021-05-04 | 2026-01-28 |
| Trial to Promote Recovery From COVID-19 With Endocrine Therapy Bicalutamide 150 Mg Oral Tablet - COVID-19, SARS-CoV 2 | Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2021-04-01 | 2021-03-05 | |
| Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Apalutamide, Bicalutamide, Biospecimen Collection - Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 | Phase 3 | Active not recruiting | NRG Oncology | 2753 | 2021-01-21 | 2026-08-17 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients Leuprorelin, Goserelin, Triptorelin - Prostatic Neoplasms | Phase 4 | Unknown | Wonju Severance Christian Hospital | 164 | 2020-01-23 | 2021-07-29 |
| Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients Nivolumab, Ipilimumab, Bicalutamide - Breast Neoplasm Female, Breast Cancer | Phase 2 | Active not recruiting | Providence Health & Services | 30 | 2019-04-03 | 2026-04-13 |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Abiraterone, Bicalutamide, Degarelix - Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 1273 | 2018-09-24 | 2026-10-08 |
| Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery HSV-Tk, Valacyclovir, Bicalutamide - High-risk Prostate Cancer, Prostate Cancer | Phase 2 | Recruiting | The Methodist Hospital Research Institute | 60 | 2018-08-02 | 2021-04-06 |
| Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer Docetaxel, Degarelix, Bicalutamide - Prostate Cancer | Early Phase 1 | Completed | University of Wisconsin, Madison | 30 | 2018-01-17 | 2024-05-03 |
| Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509) GnRH, Bicalutamide, Salvage radiation - Prostate Cancer | Phase 2 | Unknown | Dana-Farber Cancer Institute | 345 | 2017-11-24 | 2024-05-14 |
Showing 20 of 84. Sign in to see all of them.
Prostatic Neoplasms (67) · Breast Neoplasms (6) · Bulbo-Spinal Atrophy, X-Linked (3) · Neoplasm Metastasis (3) · Neoplasms (3) · Anemia (1) · Blast Crisis (1) · COVID-19 (1) · Carcinoma, Renal Cell (1) · Coronavirus Infections (1) · Familial Testotoxicosis (1) · Glioblastoma (1) · Glioma (1) · Gynecomastia (1) · Hematologic Neoplasms (1)
National Cancer Institute (NCI) (8) · AstraZeneca (5) · M.D. Anderson Cancer Center (5) · Dana-Farber Cancer Institute (3) · Ferring Pharmaceuticals (3) · Mayo Clinic (3) · NRG Oncology (3) · Radiation Therapy Oncology Group (3) · SWOG Cancer Research Network (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · University of Wisconsin, Madison (3) · City of Hope Medical Center (2) · Fudan University (2) · OHSU Knight Cancer Institute (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2)
United States (65) · Canada (11) · France (5) · United Kingdom (5) · Germany (4) · Netherlands (4) · Belgium (3) · China (3) · Denmark (3) · Spain (3) · Finland (2) · Ireland (2) · Italy (2) · Mexico (2) · Norway (2)
Christopher Logothetis (2) · Kenneth Pienta, MD (2) · Mary-Ellen Taplin, MD (2) · Robert DiPaola (2) · Ajjai Alva, M.D. (1) · Andrew K. Lee, MD (1) · Anna C Ferrari (1) · Anna Ferrari, MD (1) · Arthur Hung (1) · Brian Chapin (1) · Catherine H Marshall, MD/MPH (1)
PMID 34350976, PMID 22129214, PMID 30189902, PMID 18309951, PMID 18349405, PMID 18990504, PMID 19029421, PMID 20818327, PMID 21502546, PMID 22500884, PMID 22928480, PMID 23257248, PMID 23258223, PMID 24993934, PMID 25534388, PMID 25847934, PMID 26209502, PMID 26681677, PMID 26774508, PMID 26811535, PMID 27459586, PMID 27497762, PMID 27756786, PMID 28146658, PMID 29624463, PMID 31434793, PMID 32067679, PMID 32215583, PMID 33341447, PMID 33496795, PMID 33570548, PMID 33727260, PMID 34621011, PMID 35446628, PMID 35737923, PMID 35780048, PMID 35790016, PMID 36120850, PMID 36596347, PMID 37526936, PMID 38320143, PMID 38424319, PMID 38980676, PMID 39863139, PMID 41609418, PMID 4625049
2008 (3), U10CA180868 (3), P30CA015083 (2), P30CA016672 (2), P30CA033572 (2), U10CA021115 (2), U10CA032102 (2), N01CM00032 (1), N01CM62201 (1), N01CM62203 (1), N01CM62205 (1), N01CM62206 (1), P30CA008748 (1), P30CA014520 (1), P30CA022453 (1)